Thought Leadership
ICON experts frequently present at industry events and author or contribute to industry publications. The following are some recent articles.
- 09 May 2013
Biomarker Analysis: The Intersection of Research and Healing
- 31 March 2013
10th Anniversary Edition, Women in Biotechnology
International Women’s Week: Dr Anuradha Rajput, MD, ICON Central Laboratories, India, speaks about how one needs to have a work-life balance to be happy
- 31 March 2013
Circulating Tumor Cell Testing in Clinical Trials
By Tom McCloskey, Carla Hill, Chengsen Xue of ICON Development of new anti-tumor drugs is time consuming and costly. Is there an effective pharmacodynamic biomarker able to predict early success or failure of a drug candidate in development?
- 28 February 2013
Integrated Methodologies for the Early Assessment of Cardiovascular Safety
Contract Pharma - Integrated methodologies for early assessment. By Cyril Clarke, ICON.
- 05 February 2013
Cell-Based Testing in Central Laboratories
Outsourcing is a growing trend in the pharmaceutical industry. Demands for central laboratory testing using complex cell-based assays throughout all phases of drug development are on the rise.
- 31 January 2013
Dr Rajput: Enjoy challenges to overcome them
Dr Anuradha Rajput, managing director, ICON Central Laboratories, India, speaks about her scientific journey and how her science-oriented aptitude has helped spearhead Icon into becoming a prominent CRO in India
- 01 December 2012
Decentralisation of Imaging: Benefits and caveats for sponsors
Contract Pharma magazine November 2012 - Dr. Gregory V. Goldmacher of ICON Medical Imaging reviews recent suggestions by the FDA Oncologic Drugs Advisory Committee (ODAC) for the interpretation of radiological images from clinical trials that target solid tumors, and for which progression-free survival (PFS) is a key endpoint.
- 08 November 2012
An Inside View - PharmaAsia.com
In recent years, the use of imaging in the pre-clinical stages of drug development has exploded, perhaps most markedly in Asia Pacific region. Valerie Treyer talks about the role of Imaging biomarkers in early-phase development.
- 01 June 2012
The Value of Strategic Epidemilogoy to Inform Product Development and Commercialisation
PharmaVoice, June 2012. Contributed by Adrian Levy, PH.D., Senior Scientific Advisor, Oxford Outcomes, an ICON plc company and Nigel Gregson, Partner, PriceSpective an ICON plc company
- 01 May 2012
Thinking Allowed
ICT finds out what motivates Steve Cutler of ICON Clinical Research Services, and where he sees the industry heading.
